inclusion criteria: * age ≥18 years, male or female; * confirmed sars-cov-2 infection as determined by reverse transcription - polymerase chain reaction(rt -pcr) in any specimen collected within 5 days prior to randomization. note: rt-pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country; * patients with mild or moderate covid-19. * initial onset of signs/symptoms attributable to covid -19 within 3 days prior to the day of randomization and at least one of the specified signs/symptoms attributable to covid -19 present on the day of randomization; * women of childbearing potential who have a negative serum or urine pregnancy test prior to the first study dose; * patient who is willing to cooperate and able to participate in the trial, adhered to all requirements of the protocol, and provided written informed consent.

inclusion criteria: * age ≥18 years, male or female; * confirmed sars-cov-2 infection as determined by reverse transcription - polymerase chain reaction(rt -pcr) in any specimen collected within 5 days prior to randomization. note: rt-pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country; * patients with mild or moderate covid-19. * initial onset of signs/symptoms attributable to covid -19 within 3 days prior to the day of randomization and at least one of the specified signs/symptoms attributable to covid -19 present on the day of randomization; * women of childbearing potential who have a negative serum or urine pregnancy test prior to the first study dose; * patient who is willing to cooperate and able to participate in the trial, adhered to all requirements of the protocol, and provided written informed consent.

inclusion criteria: age ≥18 years, male or female; confirmed sars-cov-2 infection as determined by reverse transcription - polymerase chain reaction(rt -pcr) in any specimen collected within 5 days prior to randomization. note: rt-pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country; patients with mild or moderate covid-19. initial onset of signs/symptoms attributable to covid -19 within 3 days prior to the day of randomization and at least one of the specified signs/symptoms attributable to covid -19 present on the day of randomization; women of childbearing potential who have a negative serum or urine pregnancy test prior to the first study dose; patient who is willing to cooperate and able to participate in the trial, adhered to all requirements of the protocol, and provided written informed consent.

inclusion criteria: age ≥18 years, male or female; confirmed sars-cov-2 infection as determined by reverse transcription - polymerase chain reaction(rt -pcr) in any specimen collected within 5 days prior to randomization. note: rt-pcr is the preferred method; however, with evolving approaches to laboratory confirmation of sars-cov-2 infection, other molecular or antigen tests that detect viral rna or protein are allowed if authorized for use in the country; patients with mild or moderate covid-19. initial onset of signs/symptoms attributable to covid -19 within 3 days prior to the day of randomization and at least one of the specified signs/symptoms attributable to covid -19 present on the day of randomization; women of childbearing potential who have a negative serum or urine pregnancy test prior to the first study dose; patient who is willing to cooperate and able to participate in the trial, adhered to all requirements of the protocol, and provided written informed consent.